1
|
Jusino S, Rivera-Rivera Y, Chardón-Colón C, Rodríguez-Rodríguez PC, Román-González J, Juliá-Hernández VS, Isidro A, Mo Q, Saavedra HI. Sustained Shugoshin 1 downregulation reduces tumor growth and metastasis in a mouse xenograft tumor model of triple-negative breast cancer. Cell Div 2023; 18:6. [PMID: 37122033 PMCID: PMC10150544 DOI: 10.1186/s13008-023-00088-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Accepted: 04/11/2023] [Indexed: 05/02/2023] Open
Abstract
BACKGROUND Triple-negative breast cancer (TBNC) is an aggressive breast cancer subtype with a poor prognosis. Shugoshin-1 (SGO1) protects chromatids from early separation. Previous studies from our group have demonstrated that transient SGO1 downregulation suppresses early stages of metastasis (the epithelial-to-mesenchymal transition, or EMT, cell invasion, and cell migration) in TNBC cells. Thus, the inhibition of SGO1 activity may represent a potential therapeutic intervention against cancers that progress to metastasis. Therefore, we aimed to investigate the effects of sustained shRNA-mediated SGO1 downregulation on tumor growth and metastasis in TBNC. To that end, female NOD-SCID Gamma (NSG) mice were injected with 2.5 × 106 shRNA Control (n = 10) or shRNA SGO1 (n = 10) MDA-MB-231 cells. After eight weeks, the number of mice with metastasis to the lymph nodes was calculated. Primary and metastatic tumors, as well as lung and liver tissue, were harvested, measured, sectioned, and stained with hematoxylin and eosin (H&E) stain. RESULTS Tumor growth and metastasis to the lymph nodes and lungs were significantly reduced in the shRNA SGO1-treated mice group, while metastasis to the liver tends to be lower in cells with downregulated SGO1, but it did not reach statistical significance. Furthermore, sustained SGO1 downregulation significantly reduced cell proliferation, cell migration, and invasion which correlated with lower levels of Snail, Slug, MMP2, MMP3, and MMP9. CONCLUSION The supression of SGO1 activity in TNBC harboring dysregulated expression of SGO1 may be a potential target for preventing breast cancer growth and metastasis.
Collapse
Affiliation(s)
- Shirley Jusino
- Department of Basic Sciences, Ponce Health Sciences University-Ponce Research Institute, 395 Zona Industrial Reparada 2, Ponce, Puerto Rico, 00716-2348, USA
| | - Yainyrette Rivera-Rivera
- Department of Basic Sciences, Ponce Health Sciences University-Ponce Research Institute, 395 Zona Industrial Reparada 2, Ponce, Puerto Rico, 00716-2348, USA
| | - Camille Chardón-Colón
- Department of Basic Sciences, Ponce Health Sciences University-Ponce Research Institute, 395 Zona Industrial Reparada 2, Ponce, Puerto Rico, 00716-2348, USA
| | - Patricia C Rodríguez-Rodríguez
- Department of Biology, University of Puerto Rico-Ponce, 2151 Avenida Santiago de los Caballeros, Ponce, Puerto Rico, 00716, USA
| | - Janeishly Román-González
- Department of Basic Sciences, Ponce Health Sciences University-Ponce Research Institute, 395 Zona Industrial Reparada 2, Ponce, Puerto Rico, 00716-2348, USA
| | - Valeria S Juliá-Hernández
- Department of Basic Sciences, Ponce Health Sciences University-Ponce Research Institute, 395 Zona Industrial Reparada 2, Ponce, Puerto Rico, 00716-2348, USA
| | - Angel Isidro
- Department of Basic Sciences, Division of Physiology, Ponce Health Sciences University-Ponce Research Institute, 395 Zona Industrial Reparada 2, Ponce, Puerto Rico, 00716-2348, USA
| | - Qianxing Mo
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, Florida, 33612, USA
| | - Harold I Saavedra
- Department of Basic Sciences, Ponce Health Sciences University-Ponce Research Institute, 395 Zona Industrial Reparada 2, Ponce, Puerto Rico, 00716-2348, USA.
- Department of Basic Sciences, Division of Pharmacology and Cancer Biology, Ponce Health Sciences University-Ponce Research Institute, 7004, Ponce, Puerto Rico, 00732-7004, USA.
| |
Collapse
|
2
|
Jusino S, Fadul CE, Dillon P. Systematic review of the management of brain metastases from hormone receptor positive breast cancer. J Neurooncol 2023; 162:45-57. [PMID: 36884200 PMCID: PMC10049940 DOI: 10.1007/s11060-023-04276-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Accepted: 02/23/2023] [Indexed: 03/09/2023]
Abstract
INTRODUCTION Brain metastases are a common cause of morbidity and mortality in patients with breast cancer. Local central nervous system (CNS) directed therapies are usually the first line treatment for breast cancer brain metastases (BCBM), but those must be followed by systemic therapies to achieve long-term benefit. Systemic therapy for hormone receptor (HR+) breast cancer has evolved in the last 10 years, but their role when brain metastases occur is uncertain. METHODS We performed a systematic review of the literature focused on management of HR+ BCBM by searching Medline/PubMed, EBSCO, and Cochrane databases. The PRISMA guidelines were used for systematic review. RESULTS Out of 807 articles identified, 98 fulfilled the inclusion criteria in their relevance to the management of HR+ BCBM. CONCLUSIONS Similar to brain metastases from other neoplasms, local CNS directed therapies are the first line treatment for HR+ BCBM. Although the quality of evidence is low, after local therapies, our review supports the combination of targeted and endocrine therapies for both CNS and systemic management. Upon exhaustion of targeted/endocrine therapies, case series and retrospective reports suggest that certain chemotherapy agents are active against HR+ BCBM. Early phase clinical trials for HR+ BCBM are ongoing, but there is a need for prospective randomized trials to guide management and improve patients' outcome.
Collapse
Affiliation(s)
| | - Camilo E Fadul
- Division of Neuro-Oncology, Department of Neurology, University of Virginia, Charlottesville, VA, 22908, USA
| | - Patrick Dillon
- Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, 22908, USA.
| |
Collapse
|
3
|
Rodríguez Rodríguez PC, Jusino S, Rivera Rivera Y, Chardón Colón C, Román González J, Saavedra H. Shugoshin‐1 Depletion Reduces Tumor Growth in Triple‐Negative Breast Cancer. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r5985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Shirley Jusino
- Department of Basic Sciences, Division of Pharmacology and Cancer BiologyPonce Health Sciences University‐Ponce Research InstitutePoncePR
| | - Yainyrette Rivera Rivera
- Department of Basic Sciences, Division of Pharmacology and Cancer BiologyPonce Health Sciences University‐Ponce Research InstitutePoncePR
| | - Camille Chardón Colón
- Department of Basic Sciences, Division of BiochemistryPonce Health Sciences University‐Ponce Research InstitutePoncePR
| | - Janeishly Román González
- Department of Basic Sciences, Division of Pharmacology and Cancer BiologyPonce Health Sciences University‐Ponce Research InstitutePoncePR
| | - Harold Saavedra
- Department of Basic Sciences, Division of Pharmacology and Cancer BiologyPonce Health Sciences University‐Ponce Research InstitutePoncePR
| |
Collapse
|
4
|
Jusino S, Rivera-Rivera Y, Chardón-Colón C, Ruiz-Justiz AJ, Vélez-Velázquez J, Isidro A, Cruz-Robles ME, Bonilla-Claudio M, Armaiz-Pena GN, Saavedra HI. E2F3 drives the epithelial-to-mesenchymal transition, cell invasion, and metastasis in breast cancer. Exp Biol Med (Maywood) 2021; 246:2057-2071. [PMID: 34365840 DOI: 10.1177/15353702211035693] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
E2F3 is a transcription factor that may initiate tumorigenesis if overexpressed. Previously, we demonstrated that E2F3 mRNA is overexpressed in breast cancer and that E2F3 overexpression results in centrosome amplification and unregulated mitosis, which can promote aneuploidy and chromosome instability to initiate and sustain tumors. Further, we demonstrated that E2F3 leads to overexpression of the mitotic regulator Shugoshin-1, which until recently had unknown roles in cancer. This study aims to evaluate the roles of E2F3 and Shugoshin-1 in breast cancer metastatic potential. Here we demonstrated that E2F3 and Shugoshin-1 silencing leads to reduced cell invasion and migration in two mesenchymal triple-negative breast cancer (TNBC) cell lines (MDA-MB-231 and Hs578t). Moreover, E2F3 and Shugoshin-1 modulate the expression of epithelial-to-mesenchymal transition-associated genes such as Snail, E-Cadherin, and multiple matrix metalloproteinases. Furthermore, E2F3 depletion leads to reductions in tumor growth and metastasis in NOD-scid Gamma mice. Results from this study suggest a key role for E2F3 and a novel role for Shugoshin-1 in metastatic progression. These results can further help in the improvement of TNBC targeted therapies by interfering with pathways that intersect with the E2F3 and Shugoshin-1 signaling pathways.
Collapse
Affiliation(s)
- Shirley Jusino
- Department of Basic Sciences, Division of Pharmacology and Cancer Biology, Ponce Health Sciences University-Ponce Research Institute, Ponce 00716-2348, Puerto Rico
| | - Yainyrette Rivera-Rivera
- Department of Basic Sciences, Division of Pharmacology and Cancer Biology, Ponce Health Sciences University-Ponce Research Institute, Ponce 00716-2348, Puerto Rico
| | - Camille Chardón-Colón
- Department of Basic Sciences, Division of Biochemistry, Ponce Health Sciences University-Ponce Research Institute, Ponce 00716-2348, Puerto Rico
| | | | | | - Angel Isidro
- Department of Basic Sciences, Division of Physiology, Ponce Health Sciences University-Ponce Research Institute, Ponce 00716-2348, Puerto Rico
| | - Melanie E Cruz-Robles
- Department of Basic Sciences, Division of Microbiology, Ponce Health Sciences University-Ponce Research Institute, Ponce 00716-2348, Puerto Rico
| | - Margarita Bonilla-Claudio
- Department of Basic Sciences, Division of Pharmacology and Cancer Biology, Ponce Health Sciences University-Ponce Research Institute, Ponce 00716-2348, Puerto Rico
| | - Guillermo N Armaiz-Pena
- Department of Basic Sciences, Division of Pharmacology and Cancer Biology, Ponce Health Sciences University-Ponce Research Institute, Ponce 00716-2348, Puerto Rico
| | - Harold I Saavedra
- Department of Basic Sciences, Division of Pharmacology and Cancer Biology, Ponce Health Sciences University-Ponce Research Institute, Ponce 00716-2348, Puerto Rico
| |
Collapse
|
5
|
Rivera-Rivera Y, Marina M, Jusino S, Lee M, Velázquez JV, Chardón-Colón C, Vargas G, Padmanabhan J, Chellappan SP, Saavedra HI. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells. Sci Rep 2021; 11:9016. [PMID: 33907253 PMCID: PMC8079711 DOI: 10.1038/s41598-021-88512-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Accepted: 04/13/2021] [Indexed: 02/07/2023] Open
Abstract
Nek2 (NIMA-related kinase 2) is a serine/threonine-protein kinase that localizes to centrosomes and kinetochores, controlling centrosome separation, chromosome attachments to kinetochores, and the spindle assembly checkpoint. These processes prevent centrosome amplification (CA), mitotic dysfunction, and chromosome instability (CIN). Our group and others have suggested that Nek2 maintains high levels of CA/CIN, tumor growth, and drug resistance. We identified that Nek2 overexpression correlates with poor survival of breast cancer. However, the mechanisms driving these phenotypes are unknown. We now report that overexpression of Nek2 in MCF10A cells drives CA/CIN and aneuploidy. Besides, enhanced levels of Nek2 results in larger 3D acinar structures, but could not initiate tumors in a p53+/+ or a p53-/- xenograft model. Nek2 overexpression induced the epithelial-to-mesenchymal transition (EMT) while its downregulation reduced the expression of the mesenchymal marker vimentin. Furthermore, either siRNA-mediated downregulation or INH6's chemical inhibition of Nek2 in MDA-MB-231 and Hs578t cells showed important EMT changes and decreased invasion and migration. We also showed that Slug and Zeb1 are involved in Nek2 mediated EMT, invasion, and migration. Besides its role in CA/CIN, Nek2 contributes to breast cancer progression through a novel EMT mediated mechanism.
Collapse
Affiliation(s)
- Yainyrette Rivera-Rivera
- Division of Pharmacology and Cancer Biology, Department of Basic Sciences, Ponce Health Sciences University/Ponce Research Institute, PO Box 7004, Ponce, 00716-2348, Puerto Rico
| | - Mihaela Marina
- MediTech Media, Two Ravinia Drive, Suite 605, Atlanta, GA, 30346, USA
| | - Shirley Jusino
- Division of Pharmacology and Cancer Biology, Department of Basic Sciences, Ponce Health Sciences University/Ponce Research Institute, PO Box 7004, Ponce, 00716-2348, Puerto Rico
| | - Miyoung Lee
- Department of Pediatrics, Aflac Cancer and Blood Disorder Center, Emory University School of Medicine, Atlanta, GA, 30322, USA
| | - Jaleisha Vélez Velázquez
- Department of Biology, University of Puerto Rico-Ponce, 2151 Santiago de los Caballeros Avenue, Ponce, 00716, Puerto Rico
| | - Camille Chardón-Colón
- Division of Pharmacology and Cancer Biology, Department of Basic Sciences, Ponce Health Sciences University/Ponce Research Institute, PO Box 7004, Ponce, 00716-2348, Puerto Rico
| | - Geraldine Vargas
- Division of Pharmacology and Cancer Biology, Department of Basic Sciences, Ponce Health Sciences University/Ponce Research Institute, PO Box 7004, Ponce, 00716-2348, Puerto Rico
| | - Jaya Padmanabhan
- Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA
| | - Srikumar P Chellappan
- Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA
| | - Harold I Saavedra
- Division of Pharmacology and Cancer Biology, Department of Basic Sciences, Ponce Health Sciences University/Ponce Research Institute, PO Box 7004, Ponce, 00716-2348, Puerto Rico.
| |
Collapse
|
6
|
Colón-Marrero S, Jusino S, Rivera-Rivera Y, Saavedra HI. Mitotic kinases as drivers of the epithelial-to-mesenchymal transition and as therapeutic targets against breast cancers. Exp Biol Med (Maywood) 2021; 246:1036-1044. [PMID: 33601912 DOI: 10.1177/1535370221991094] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Biological therapies against breast cancer patients with tumors positive for the estrogen and progesterone hormone receptors and Her2 amplification have greatly improved their survival. However, to date, there are no effective biological therapies against breast cancers that lack these three receptors or triple-negative breast cancers (TNBC). TNBC correlates with poor survival, in part because they relapse following chemo- and radio-therapies. TNBC is intrinsically aggressive since they have high mitotic indexes and tend to metastasize to the central nervous system. TNBCs are more likely to display centrosome amplification, an abnormal phenotype that results in defective mitotic spindles and abnormal cytokinesis, which culminate in aneuploidy and chromosome instability (known causes of tumor initiation and chemo-resistance). Besides their known role in cell cycle control, mitotic kinases have been also studied in different types of cancer including breast, especially in the context of epithelial-to-mesenchymal transition (EMT). EMT is a cellular process characterized by the loss of cell polarity, reorganization of the cytoskeleton, and signaling reprogramming (upregulation of mesenchymal genes and downregulation of epithelial genes). Previously, we and others have shown the effects of mitotic kinases like Nek2 and Mps1 (TTK) on EMT. In this review, we focus on Aurora A, Aurora B, Bub1, and highly expressed in cancer (Hec1) as novel targets for therapeutic interventions in breast cancer and their effects on EMT. We highlight the established relationships and interactions of these and other mitotic kinases, clinical trial studies involving mitotic kinases, and the importance that represents to develop drugs against these proteins as potential targets in the primary care therapy for TNBC.
Collapse
Affiliation(s)
- Stephanie Colón-Marrero
- Department of Basic Sciences, Division of Pharmacology and Cancer Biology, 6650Ponce Health Sciences University/Ponce Research Institute, Ponce, PR 00732, USA
| | - Shirley Jusino
- Department of Basic Sciences, Division of Pharmacology and Cancer Biology, 6650Ponce Health Sciences University/Ponce Research Institute, Ponce, PR 00732, USA
| | - Yainyrette Rivera-Rivera
- Department of Basic Sciences, Division of Pharmacology and Cancer Biology, 6650Ponce Health Sciences University/Ponce Research Institute, Ponce, PR 00732, USA
| | - Harold I Saavedra
- Department of Basic Sciences, Division of Pharmacology and Cancer Biology, 6650Ponce Health Sciences University/Ponce Research Institute, Ponce, PR 00732, USA
| |
Collapse
|
7
|
Jusino S, Chellappan SP, Saavedra HI. Role of E2F3 and shugoshin I in epithelial-to-mesenchymal transition and cell invasion in breast cancer. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e13100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13100 Background: Triple-negative breast cancer (TNBC) is the most aggressive and poorly prognostic breast cancer subtype, yet there are currently no biological therapies against this subtype. Our laboratory is finding the sources of novel biological targets in TNBC by studying the E2F transcription factors, which are essential for cellular proliferation and maintenance of genomic stability. While the deregulated Rb/E2F pathway signals the epithelial-to-mesenchymal transition (EMT), the underlining mechanism of how E2Fs drive EMT in TNBC remains unknown. We recently published that the E2F transcriptional activators (E2Fs) are overexpressed in the vast majority of TNBC and that their overexpression upregulates mitotic kinases such as TTK, which we have shown to induce EMT and invasion in TNBC cells. We also demonstrated that the E2Fs maintain genomic integrity in part through Shugoshin I (SGO1), which normally controls chromosome cohesion; however, the role of SGO1 in EMT in breast cancer is unknown. Our hypothesis is that E2F3 and SGO1 are highly expressed in TNBC and that their overexpression modulates EMT genes, thus promoting cell invasion. Methods: To test our hypothesis, we conducted siRNA transfection to knockdown E2F3 and SGO1 in MDA-MB-231 and Hs578t, which are TNBC cells. After 48 hours, we evaluated mRNA levels of EMT-related genes after E2F3 or SGO1 depletion using RT-PCR analysis. We also evaluated the effects of SGO1 depletion in protein localization by immunofluorescence. Furthermore, we evaluated the invasive behavior of MDA-MB-231 and Hs578t cells after SGO1 depletion using a Boyden Chamber Assay. Results: Our results demonstrate that E2F3 and SGO1 depletion decrease MMP3 mRNA levels. Moreover, E2F3 and SGO1 depletion restore E-cadherin expression and localization. Furthermore, E2F3 and SGO1 depletion significantly reduce cell invasion in MDA-MB-231 and Hs578t cells. Conclusions: Our results suggest that SGO1 is a promising drug target for breast cancer metastasis since EMT and invasion are essential early steps in breast cancer metastasis and E2F3 is presently undruggable.
Collapse
|
8
|
Jusino S, Saavedra HI. Abstract P6-07-06: Shugoshin I signals epithelial-mesenchymal transition and promotes cell invasion in breast cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p6-07-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Despite being the most aggressive and poorly prognostic breast cancer subtype, there are currently no biological therapies against triple-negative (TN, or ER-PR-Her2-) breast cancers. Our laboratory is finding the sources of novel biological targets in TNBC by studying the E2F transcription factors, which are essential for cellular proliferation and maintenance of genomic stability. We recently published that the E2F transcriptional activators are overexpressed in the vast majority of TNBC and can dictate the high percentage of mitotic cells in mammary tumors. We also demonstrated that that the E2Fs control multiple mitotic regulators and maintain genomic integrity through Shugoshin I (SGO1) and BubR1. SGO1 is essential for chromosome segregation by preventing premature dissociation of the cohesion complex and sister chromatids after prophase. Until recently, SGO1 research was restricted to embryogenesis; however, recent studies have shown a role for SGO1 in tumorigenesis and epithelial-mesenchymal transition (EMT), but none have been done in breast cancer. Thus, we investigated SGO1 expression and genetic alteration in open databases such as KM-Plotter and cBioPortal and found that SGO1 is highly expressed in triple-negative breast cancer subtype and that its expression correlates with poor prognostic factors. Therefore, we decided to investigate the role of SGO1 in breast cancer EMT and cell invasion. Our hypothesis is that SGO1 modulates EMT genes, thus promoting cell invasion. To test our hypothesis, we conducted siRNA transfection to knockdown SGO1 in MDA-MB-231 and Hs578t, which are TNBC cells. After 48 hours, we evaluated mRNA levels of EMT-related genes after SGO1 depletion using RT-PCR analysis. We also evaluated the effects of SGO1 depletion in protein localization by immunofluorescence analysis. Furthermore, we evaluated the invasive behavior of MDA-MB-231 and Hs578t cells after SGO1 depletion using a Boyden Chamber Assay. Our results demonstrate that SGO1 depletion signals EMT by decreasing N-cadherin and increasing E-cadherin mRNA levels. SGO1 depletion also restores protein expression of E-cadherin in MDA-MB-231 cells. Strikingly, SGO1 depletion significantly reduces invasion in MDA-MB-231 and Hs578t cells. Our results suggest that SGO1 is a promising drug target for breast cancer metastasis since EMT and invasion are essential early steps in breast cancer metastasis. Currently, we are evaluating SGO1 expression in tissue microarrays derived from breast cancer patients (including Luminal and TNBC subtypes), in order to determine the percentage of those patients expressing Sgo1, as well as to establish important correlations with surrogate markers of prognosis (EMT, proliferation, mitosis). Our results may help establish new druggable targets in order to prevent and reduce metastasis in TNBC patients.
Citation Format: Shirley Jusino, Harold I. Saavedra. Shugoshin I signals epithelial-mesenchymal transition and promotes cell invasion in breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-07-06.
Collapse
|
9
|
Abstract
The epithelial-to-mesenchymal transition (EMT) is a complex cellular process in which epithelial cells acquire mesenchymal properties. EMT occurs in three biological settings: development, wound healing and fibrosis, and tumor progression. Despite occurring in three independent biological settings, EMT signaling shares some molecular mechanisms that allow epithelial cells to de-differentiate and acquire mesenchymal characteristics that confer cells invasive and migratory capacity to distant sites. Here we summarize the molecular mechanism that delineates EMT and we will focus on the role of E2 promoter binding factors (E2Fs) in EMT during tumor progression. Since the E2Fs are presently undruggable due to their control in numerous pivotal cellular functions and due to the lack of selectivity against individual E2Fs, we will also discuss the role of three mitotic regulators and/or mitotic kinases controlled by the E2Fs (NEK2, Mps1/TTK, and SGO1) in EMT that can be useful as drug targets. Impact statement The study of the epithelial to mesenchymal transition (EMT) is an active area of research since it is one of the early intermediates to invasion and metastasis—a state of the cancer cells that ultimately kills many cancer patients. We will present in this review that besides their canonical roles as regulators of proliferation, unregulated expression of the E2F transcription factors may contribute to cancer initiation and progression to metastasis by signaling centrosome amplification, chromosome instability, and EMT. Since our discovery that the E2F activators control centrosome amplification and mitosis in cancer cells, we have identified centrosome and mitotic regulators that may represent actionable targets against EMT and metastasis in cancer cells. This is impactful to all of the cancer patients in which the Cdk/Rb/E2F pathway is deregulated, which has been estimated to be most cancer patients with solid tumors.
Collapse
Affiliation(s)
- Shirley Jusino
- Basic Sciences Department, Division of Pharmacology and Toxicology, Ponce Research Institute, Ponce Health Sciences University, Ponce PR 00732, USA
| | - Harold I Saavedra
- Basic Sciences Department, Division of Pharmacology and Toxicology, Ponce Research Institute, Ponce Health Sciences University, Ponce PR 00732, USA
| |
Collapse
|
10
|
Jusino S, Hidalgo-Vargas MJ, Padmanabhan J, Chellapppan SP, Saavedra HI. Abstract 1881: Role of E2F activators and mitotic regulators controlled by E2Fs in EMT, invasion, and metastasis of breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-1881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The E2 Promoter Binding Factors (E2Fs) are a group of eight transcription factors that are highly deregulated in breast cancer and control several cellular processes, including proliferation and centrosome duplication. Broadly, E2Fs can be divided into transcriptional activators and repressors based on their role in gene transcription. In addition to their traditional cell cycle functions, it is known that deregulated Rb/E2F pathway signals the epithelial-to-mesenchymal transition (EMT); yet the underlining mechanism of how E2Fs drive EMT in breast cancer remains unknown. Published data from our laboratory demonstrates that overexpression of activating E2Fs leads to increased expression of mitotic regulators such as BUBR1, MPS1 (TTK), and SGO1, among others. Furthermore, published data from our laboratory shows that TTK promotes mesenchymal signaling through several mechanisms in breast cancer. Hence, we are investigating to what extent deregulation of E2F activators promotes EMT, invasion, and metastasis through the remaining mitotic regulators. Our hypothesis is that the overexpression of E2F activators contributes to tumorigenesis by promoting EMT through the induction of the transcription of specific mitotic regulators, thus leading to increased invasion and metastasis. To test our hypothesis, E2Fs (1, 2 and 3a) were knockdown individually or in combination of two or three E2F activators simultaneously using specific siRNAs sequences in MDA-MB-231 cells. After 48 hours, western blot analysis was performed to confirm the knockdown and to evaluate the effects of knockdown of these E2Fs on protein levels of mitotic regulators and EMT markers. Real-time PCR was performed to evaluate EMT mRNA expression levels. Additionally, a wound healing assay was conducted to evaluate cell migration, as an indicator of metastasis. All experiments were performed in triplicates and a non-parametric Mann Whitney test was used to evaluate statistical significance. Our results show that knockdown of E2F1 and the combination of all activating E2Fs decreased the expression of mitotic regulators and EMT proteins. Likewise, knockdown of E2Fs decreased the expression of certain EMT genes (but not all) and knockdown of E2F1 decreased cell migration. These results suggest that E2F1 has a prominent role in breast cancer EMT and cell migration. Currently, we are exploring the effects of knockdown of E2F-controlled mitotic regulators in breast cancer EMT and cell migration.
Citation Format: Shirley Jusino, Melanie J. Hidalgo-Vargas, Jaya Padmanabhan, Srikumar P. Chellapppan, Harold I. Saavedra. Role of E2F activators and mitotic regulators controlled by E2Fs in EMT, invasion, and metastasis of breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1881.
Collapse
|
11
|
Abstract
Centrosomes serve as the major microtubule organizing centers in cells and thereby contribute to cell shape, polarity, and motility. Also, centrosomes ensure equal chromosome segregation during mitosis. Centrosome aberrations arise when the centrosome cycle is deregulated, or as a result of cytokinesis failure. A long-standing postulate is that centrosome aberrations are involved in the initiation and progression of cancer. However, this notion has been a subject of controversy because until recently the relationship has been correlative. Recently, it was shown that numerical or structural centrosome aberrations can initiate tumors in certain tissues in mice, as well as invasion. Particularly, we will focus on centrosome amplification and chromosome instability as drivers of intra-tumor heterogeneity and their consequences in cancer. We will also discuss briefly the controversies surrounding this theory to highlight the fact that the role of both centrosome amplification and chromosome instability in cancer is highly context-dependent. Further, we will discuss single-cell sequencing as a novel technique to understand intra-tumor heterogeneity and some therapeutic approaches to target chromosome instability.
Collapse
Affiliation(s)
- Shirley Jusino
- Basic Sciences Department, Division of Pharmacology and Toxicology, Ponce Health Sciences University, Ponce Research Institute, Ponce, PR 00732, USA
| | - Fabiola M Fernández-Padín
- Basic Sciences Department, Division of Pharmacology and Toxicology, Ponce Health Sciences University, Ponce Research Institute, Ponce, PR 00732, USA
| | - Harold I Saavedra
- Basic Sciences Department, Division of Pharmacology and Toxicology, Ponce Health Sciences University, Ponce Research Institute, Ponce, PR 00732, USA
| |
Collapse
|
12
|
Jusino S, Godoy L, Albino E, Ortiz C, Hill M. Drug‐associated DNA Damage in HIV‐1 Patients taking HAART. FASEB J 2015. [DOI: 10.1096/fasebj.29.1_supplement.lb108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Shirley Jusino
- BiologyUniversity of Puerto RicoPoncePuerto RicoUnited States
| | - Lenin Godoy
- Pharmacology and ToxicologyPonce Research InstitutePoncePuerto RicoUnited States
| | - Elinette Albino
- Pharmacology and ToxicologyPonce Research InstitutePoncePuerto RicoUnited States
| | - Carmen Ortiz
- Pharmacology and ToxicologyPonce Research InstitutePoncePuerto RicoUnited States
| | - Martin Hill
- Pharmacology and ToxicologyPonce Research InstitutePoncePuerto RicoUnited States
| |
Collapse
|
13
|
Jusino S. Monocyte‐derived macrophages as an active HIV‐1 viral reservoir in patients receiving suppressive cART (145.4). FASEB J 2014. [DOI: 10.1096/fasebj.28.1_supplement.145.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Shirley Jusino
- BiologyUniversity of Puerto Rico at PoncePoncePuerto Rico
| |
Collapse
|
14
|
Jusino S, Arroyo N, Albino E, Dutil J. Functional Role of the Single Nucleotide Polymorphism located at −224 A>;G and −599 C>;T in Neuropeptide Receptor Y2 (NPY2R) Gene in Predisposition to Hypertension. FASEB J 2013. [DOI: 10.1096/fasebj.27.1_supplement.lb91] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Nelly Arroyo
- BiochemistryPonce School of Medicine & Health SciencesPoncePR
| | - Elinette Albino
- BiochemistryPonce School of Medicine & Health SciencesPoncePR
| | - Julie Dutil
- BiochemistryPonce School of Medicine & Health SciencesPoncePR
| |
Collapse
|